Optimum predictors of therapeutic outcome in HCV patients in Pakistan

被引:12
作者
Aziz, Hafsa [1 ]
Raza, Abida [1 ]
Irfan, Javaid [1 ]
机构
[1] Nucl Med Oncol & Radiotherapy Inst, Islamabad, Pakistan
关键词
HCV genotypes; treatment response; HEPATITIS-C-VIRUS; SUSTAINED VIROLOGICAL RESPONSE; INTERFERON-ALPHA THERAPY; BLOOD MONONUCLEAR-CELLS; RIBOSOME ENTRY SITE; PEGYLATED INTERFERON; RIBAVIRIN TREATMENT; PLUS RIBAVIRIN; CORE PROTEIN; GENOTYPE;
D O I
10.1002/jmv.24305
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV) constitutes a major public health issue in Pakistan. Interferon and ribavirin is used widely in routine practice in HCV infected patients in Pakistan.Treatment prediction is an important tool in therapy management. The present study aims to evaluate trends of predictive variables of treatment outcome in patients with different genotypes. The analysis comprised of 921 patients infected with different HCV genotypes. All the patients received IFN -2b combined with ribavirin for 24 weeks. Overall, 60.2% patients achieved Sustained virologic response (SVR). In females sustained virologic response (SVR) was higher in age group <40 years (77.2%) than 40-50years (60%) but in male SVR was almost equal in both age groups. We also found higher SVR with low pretreatment viral load (72.4%, P<0.0001). Sustained Virologic Response in genotype 3a was 63.1%, 3b was 55%, 1a was 36.3% and 1b was 35% 3a +3b was 55.0% and 1a+3a was 42.9%. According to multivariable logistic regression analysis age <40 years (2.0; 95%CI, 1.49-2.84; P=0.0001), low pretreatment RNA level<800,000 IU/ml (4.0; 95%CI, 2.64-6.17; P=0.0001), early virologic response at week 12 (12.3; 95%CI, 8.18-18.58; P<0.0001) and non-fatty liver (2.5; 95%CI, 3.6-6.2; P=0.005) showed significance for SVR. Nucleotide substitution in 5UTR before treatment failed to show any characteristic pattern that has correlation with sustained response. Subtype 3a showed 95% presence among patients with age <40 years while older patients showed 79.9%. J. Med. Virol. 88:100-108, 2016. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:100 / 108
页数:9
相关论文
共 49 条
[21]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[22]   Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection [J].
McHutchison, John G. ;
Everson, Gregory T. ;
Gordon, Stuart C. ;
Jacobson, Ira M. ;
Sulkowski, Mark ;
Kauffman, Robert ;
McNair, Lindsay ;
Alam, John ;
Muir, Andrew J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1827-1838
[23]  
Moatter Tariq, 2002, International Journal of Infectious Diseases, V6, P272, DOI 10.1016/S1201-9712(02)90160-8
[24]   Evolution of naturally occurring 5'non-coding region variants of Hepatitis C virus in human populations of the South American region [J].
Moratorio, Gonzalo ;
Martinez, Mariela ;
Gutierrez, Maria F. ;
Gonzalez, Katiuska ;
Colina, Rodney ;
Lopez-Tort, Fernando ;
Lopez, Lilia ;
Recarey, Ricardo ;
Schijman, Alejandro G. ;
Moreno, Maria P. ;
Garcia-Aguirre, Laura ;
Manascero, Aura R. ;
Cristina, Juan .
VIROLOGY JOURNAL, 2007, 4 (1)
[25]   New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a [J].
Ohno, T ;
Mizokami, M ;
Wu, RR ;
Saleh, MG ;
Ohba, K ;
Orito, E ;
Mukaide, M ;
Williams, R ;
Lau, JYN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :201-207
[26]   Altered T cell signalling in ageing [J].
Pawelec, G ;
Hirokawa, K ;
Fülöp, T .
MECHANISMS OF AGEING AND DEVELOPMENT, 2001, 122 (14) :1613-1637
[27]   Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels [J].
Persico, M ;
Persico, E ;
Suozzo, R ;
Conte, S ;
De Seta, M ;
Coppola, L ;
Palmentieri, B ;
Sasso, FC ;
Torella, R .
GASTROENTEROLOGY, 2000, 118 (04) :760-764
[28]   Boceprevir for Untreated Chronic HCV Genotype 1 Infection [J].
Poordad, Fred ;
McCone, Jonathan, Jr. ;
Bacon, Bruce R. ;
Bruno, Savino ;
Manns, Michael P. ;
Sulkowski, Mark S. ;
Jacobson, Ira M. ;
Reddy, K. Rajender ;
Goodman, Zachary D. ;
Boparai, Navdeep ;
DiNubile, Mark J. ;
Sniukiene, Vilma ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Bronowicki, Jean-Pierre ;
Colombato, L. ;
Curciarello, J. ;
Silva, M. ;
Tanno, H. ;
Terg, R. ;
Adler, M. ;
Langlet, P. ;
Lasser, L. ;
Nevens, F. ;
Anderson, F. ;
Bailey, R. ;
Bilodeau, M. ;
Cooper, C. ;
Feinman, S. V. ;
Heathcote, J. ;
Levstik, M. ;
Ramji, A. ;
Sherman, M. ;
Shafran, S. ;
Yoshida, E. ;
Achim, A. ;
Ben Ali, S. ;
Bigard, M-A. ;
Bonny, C. ;
Bourliere, M. ;
Boyer-Darrigrand, N. ;
Bronowicki, J-P. ;
Canva, V. ;
Couzigou, P. ;
De Ledinghen, V. ;
Guyader, D. ;
Hezode, C. ;
Larrey, D. ;
Latournerie, M. ;
Marcellin, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1195-1206
[29]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432
[30]  
Pyrpasopoulou A, 2011, J CLIN CELL IMMUNO S, V1, P1